Tenaya Therapeutics announced interim data from its MyPEAK-1 Phase 1b/2 trial showing that TN-201 gene therapy led to consistent cardiac remodeling and symptom improvements in patients with MYBPC3-associated hypertrophic cardiomyopathy (HCM). Patients in both low and high dose cohorts showed reductions in heart muscle thickening, improved heart function, and better exercise capacity, with benefits sustained up to two years in some cases. TN-201 has received PRIME designation from the EMA and is part of the FDA's Rare Disease Evidence Principles process, supporting its potential as a treatment for this severe genetic heart condition. Tenaya plans to share more long-term data later in 2026 and is working with regulators on pivotal study designs.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
